From: Long non-coding RNA H19 in atherosclerosis: what role?
Pathway | Function | Experiment | Experimental Material | Ref. |
---|---|---|---|---|
lncRNA-H19/CTCF/PKD1 | pro-angiogenesis | in vivo | aortic tissues from ApoE−/− knockout mice | (Yang et al. 2019) |
lncRNA-H19/miR-199a-5p/VEGF-A, | pro-angiogenesis | in vitro | BMSCs from mice | (Hou et al. 2018) |
lncRNA-H19/miR-29a/VEGF-A, | pro-angiogenesis | in vitro | glioma tissue specimens from patients diagnosed with glioma undergoing surgical resection, human brain microvascular endothelial cell line | (Jia et al. 2016) |
lncRNA-H19/miR-29c/VEGF-A | pro-angiogenesis | in vitro and in vivo | vascularized corneas from patients, rat model of CNV, HUVECs | (Sun et al. 2019a) |
lncRNA-H19/miR-181a/eNOS/VEGF | pro-angiogenesis | in vitro | HMEC-1 cells | (Zhu et al. 2019a) |
lncRNA-H19/EZH2/VASH1 | pro-angiogenesis | in vitro and in vivo | subcutaneous model in nude mice, HAMSCs, HUVECs | (Yuan et al. 2019) |
lncRNA-H19/STAT3 | pro-angiogenesis | in vitro, in vivo and ex vivo | carotid plaques from patients, endothelial-specific inducible lncRNA-H19 deficient mice and control littermates, aortic rings from young and aged mice, monocytes, HUVECs, hCoAECs | (Hofmann et al. 2019) |
lncRNA-H19/miR-675/Class II HDAC | anti-adipogenic | in vitro | BMSCs from human | (Huang et al. 2016) |
lncRNA-H19/miR-188/LCoR | anti-adipogenic | in vitro | BMSCs from mice | (Wang et al. 2018) |
lncRNA-H19/miR-130a/PPARγ | pro-lipid accumulation | in vitro and in vivo | mouse model of NFALD, HepG2 and Huh-7 cells for NAFLD cellular model | (Liu et al. 2019) |
lncRNA-H19/PTBP1/SREBP1c | pro-lipid accumulation | in vitro and in vivo | human liver specimens, lncRNA-H19-deleted mice, lncRNA-H19 overexpressed and PTBP1 knockdown mice, primary hepatocytes from mice | (Liu et al. 2018) |
lncRNA-H19/MBD1/PEGs | pro-adipogenic, anti-lipid accumulation | in vitro and in vivo | adipose tissues from mice exposed cold or exposed to chronic HFD feeding, PIBA cell line | (Schmidt et al. 2018) |
lncRNA-H19/miR-130b | pro-lipid accumulation, pro-inflammatory | in vitro | blood samples from atherosclerotic patients and non-atherosclerotic patients, mouse macrophages cell line (Raw264.7) | (Han et al. 2018) |
lncRNA-H19/p38&p65/NF-κB | pro-inflammatory | in vitro | blood samples from atherosclerotic patients and healthy volunteers, atherosclerotic plaque and adjacent tissues from ApoE−/− mice, VSMCs, HUVECs | (Pan 2017) |
in vitro | blood samples from atherosclerotic patients and healthy volunteers, HUVECs | (Li et al. 2019a) | ||
lncRNA-H19/let-7a/IL-6 | pro-inflammatory | in vivo and ex vivo | human AAA samples and adjacent normal aortic tissues, mouse model of AAA, ApoE−/− mice, mouse aortic VSMCs, mouse macrophages cell line (Raw264.7) | (Sun et al. 2019b) |
lncRNA-H19/let-7/periostin | pro-inflammatory | in vitro | HUVECs | (Cao et al. 2019) |
lncRNA-H19/ACP5 | pro-proliferation, anti-apoptosis | in vitro and in vivo | blood samples from atherosclerotic patients and healthy subjects, mouse model of ischemic stroke, VSMCs, HUVECs | (Huang et al. 2019) |
lncRNA-H19/let-7a/cyclin D1 | pro-proliferation | in vitro and in vivo | common carotid arteries from rat model of carotid artery balloon injury, HA-VSMCs, HEK 293 T cells | (Sun et al. 2019c) |
lncRNA-H19/let-7b/AT1R | pro-proliferation | in vitro and in vivo | Serum, lung tissues and PAMSCs from rat/mouse model of PAH | (Su et al. 2018) |
lncRNA-H19/miR-148b/WNT/β-catenin | pro-proliferation, anti-apoptosis | in vitro | blood samples from atherosclerotic patient without any treatment and healthy volunteers, HA-VSMCs | (Zhang et al. 2018a) |
lncRNA-H19/miR-675/PTEN | pro-proliferation | in vitro and in vivo | common carotid arteries from rat model of carotid artery balloon injury, HA-VSMCs, HEK 293 T cells | (Lv et al. 2018) |
lncRNA-H19/miR-675-5p/Mfn2 | pro-proliferation, anti-apoptosis | in vitro and in vivo | vascular walls from rat model of carotid artery balloon injury, VSMCs | (Xu and Sun 2018) |
lncRNA-H19/HIF1α/Mdm2/p53/Bcl-2&BAX | pro-apoptosis | in vitro and in vivo | AAA samples from patients and abdominal aortic samples from organ donor controls, mouse model of AAA, mini-pigs model of AAA, HA-VSMCs | (Li et al. 2018) |
lncRNA-H19/miR-22-3p/KDM3A | alleviate MI | in vitro and in vivo | rat model of AMI, neonatal rat cardiomyocytes | (Zhang et al. 2020) |
lncRNA-H19/miR-139/Sox8 | alleviate MI | in vitro | rat embryonic cardiomyocyte cell line (H9C2) | (Gong et al. 2017) |
lncRNA-H19/YB-1 | aggravate cardiac remodeling after infarction | in vitro and in vivo | mouse model of MI, cardiomyocytes and cardiac fibroblasts from MI mice, mouse embryonic fibroblast cell line (NIH3T3) | (Choong et al. 2019) |
lncRNA-H19/miR-877-3p/Bcl-2 | alleviate myocardial I/R | in vitro and in vivo | mouse model of myocardial I/R injury, NMVCs | (Li et al. 2019b) |
lncRNA-H19/miR-103&miR-107/FADD | alleviate myocardial I/R | in vitro and in vivo | mouse model of myocardial I/R injury, rat embryonic cardiomyocyte cell line (H9C2) | (Wang et al. 2015) |
lncRNA-H19/nucleolin | alleviate myocardial I/R | in vitro and in vivo | mouse model of myocardial IP and I/R injury, rat embryonic cardiomyocyte cell line (H9C2), neonatal rat cardiomyocytes | (Chen et al. 2020) |
lncRNA-H19/miR-29b-3p/cIAP1 | alleviate myocardial I/R | in vitro | neonatal rat cardiomyocytes, rat embryonic cardiomyocyte cell line (H9C2), HEK 293 T cells | (Zhang et al. 2019) |
lncRNA-H19/miR-675/PPARα | aggravate myocardial I/R | in vitro and in vivo | mouse model of myocardial I/R injury, neonatal mouse cardiomyocytes | (Luo et al. 2019) |